Immunotherapies and immunomodulatory approaches in clinical trials - a mini review
- 12 February 2021
- journal article
- review article
- Published by Taylor & Francis Ltd in Human Vaccines & Immunotherapeutics
- Vol. 17 (7), 1897-1909
- https://doi.org/10.1080/21645515.2020.1871295
Abstract
The coronavirus disease (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created havoc worldwide. Due to the non-availability of any vaccine or drugs against COVID-19, immunotherapies involving convalescent plasma, immunoglobulins, antibodies (monoclonal or polyclonal), and the use of immunomodulatory agents to enhance immunity are valuable alternative options. Cell-based therapies including natural killer cells, T cells, stem cells along with cytokines and toll-like receptors (TLRs) based therapies are also being exploited potentially against COVID-19. Future research need to strengthen the field of developing effective immunotherapeutics and immunomodulators with a thrust of providing appropriate, affordable, convenient, and cost-effective prophylactic and treatment regimens to combat global COVID-19 crisis that has led to a state of medical emergency enforcing entire countries of the world to devote their research infrastructure and manpower in tackling this pandemic.Keywords
Funding Information
- Department of Science and Technology, Government of India (SEED/TIASN/017/2018)
This publication has 143 references indexed in Scilit:
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaThe New England Journal of Medicine, 2017
- Beneficial health applications and medicinal values of Pedicularis plants: A reviewBiomedicine & Pharmacotherapy, 2017
- Tisagenlecleucel — the first approved CAR-T-cell therapy: implications for payers and policy makersNature Reviews Clinical Oncology, 2017
- Enhanced clearance of HIV-1–infected cells by broadly neutralizing antibodies against HIV-1 in vivoScience, 2016
- Historical review of thymosin α 1 in infectious diseasesExpert Opinion on Biological Therapy, 2015
- Cancer ImmunotherapyScience, 2013
- Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatmentsOncoTargets and Therapy, 2011
- Sipuleucel-T: Prototype for Development of Anti-tumor VaccinesCurrent Oncology Reports, 2011
- Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individualsNature Medicine, 2006
- Use of convalescent plasma therapy in SARS patients in Hong KongEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004